Metabolic Dysfunction-associated Steatohepatitis
The question
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to integrate steatotic liver disease indicators into non-communicable disease policy and frameworks to meet the World Health Assembly resolution on steatotic liver disease adopted in May 2026.
Answered by Mrs Sharon Hodgson
The Government recognises the importance of the World Health Assembly’s resolution on steatotic liver disease (SLD), which marks the first time liver disease has been formally recognised as part of the global agenda on noncommunicable diseases.
We are taking action to ensure SLD is integrated within whole-system approaches and tackled effectively. This includes through NHS England’s Liver Transformation Programme, which aims to improve liver disease diagnosis and treatment through focus on the entire care pathway, ensuring a more integrated and effective approach to liver care. The programme has three workstreams, awareness and prevention, detection and diagnosis, and treatment, which will ensure outcomes are aligned with the goals of the World Health Assembly’s resolution on SLD.
Furthermore, the newly published Cardiovascular Disease Modern Service Framework is specifically designed as an integrated cardiovascular-kidney-metabolic strategy and makes specific mention of the importance of addressing metabolic associated SLD.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →